8-K: Mycotopia Therapies Restructures Shareholding with Ehave Inc., Granting Super Voting Rights

Mycotopia Therapies has entered into an agreement with its largest shareholder, Ehave Inc., exchanging common stock for a new series of super voting preferred stock, granting Ehave significant control.

Summary

• Mycotopia Therapies entered into an Exchange Agreement with Ehave Inc., its largest shareholder, on July 29, 2024.
• Ehave exchanged 9,793,754 shares of Mycotopia common stock for one share of newly designated Series A Super Voting Stock.
• The Series A Preferred stock grants the holder voting power equal to 75% of the total shares authorized to vote.
• The voting power is calculated using the formula X = 3 x Y, where X is the total votes and Y is the total authorized shares.
• The Series A Preferred stock is convertible into 9,793,754 shares of common stock at the holder's option.
• The company also amended its articles of incorporation to increase the number of authorized common shares to 467,000,000 on June 24, 2024.
• The designation of the Series A Preferred and the amendment to increase authorized common stock were filed with the state of Nevada on August 8, 2024.

Sentiment

Score: 3

Explanation: The document describes a significant shift in voting power, which is generally viewed negatively by investors as it reduces the influence of minority shareholders. The lack of positive financial news and the potential for future dilution further contribute to the low sentiment score.

Positives

• The agreement simplifies the share structure by consolidating a large block of common stock into a single preferred share.
• The conversion option provides flexibility for Ehave to convert back to common stock if desired.
• The company has taken steps to ensure sufficient authorized shares are available for potential conversion.

Negatives

• The super voting rights granted to Ehave significantly reduce the voting power of other shareholders.
• The concentration of voting power in a single shareholder could lead to potential conflicts of interest.
• The conversion of the preferred stock could potentially dilute the value of the common stock.

Risks

• The significant voting power held by Ehave could lead to decisions that are not in the best interest of all shareholders.
• The potential conversion of the Series A Preferred stock could result in a large increase in the number of outstanding common shares.
• The limited public market for the common stock could make it difficult for Ehave to sell its shares if it chooses to convert.

Future Outlook

The document does not contain specific forward-looking statements or guidance, but the restructuring of shareholding will likely have a significant impact on the company's future governance and decision-making.

Management Comments

• Ben Kaplan, Chief Executive Officer, signed the report on behalf of Mycotopia Therapies.

Industry Context

The creation of super voting stock is a relatively uncommon practice, often used to maintain control by founders or major shareholders. This move by Mycotopia Therapies suggests a desire to consolidate control within Ehave Inc., which may be a strategic move to facilitate future business plans or protect against hostile takeovers.

Comparison to Industry Standards

• The use of super voting stock is not a standard practice in the broader market, with most companies opting for a one-share-one-vote structure.
• Companies like Google (Alphabet) have used dual-class share structures to maintain control by founders, but this is different from the super voting structure used by Mycotopia.
• The 75% voting power granted to Ehave is a significant level of control, which is not typical in most publicly traded companies.
• The conversion ratio of 1 preferred share to 9,793,754 common shares is a very high ratio, indicating the significant voting power attached to the preferred share.

Corporate Governance

Related Party Transactions

• The Exchange Agreement with Ehave Inc. is a related party transaction as Ehave is the largest shareholder of Mycotopia Therapies.

Stakeholder Impact

• Shareholders other than Ehave Inc. will experience a significant reduction in their voting power.
• The potential conversion of the Series A Preferred stock could dilute the value of common stock.
• The concentration of voting power could lead to decisions that may not be in the best interest of all stakeholders.

Next Steps

• The company will need to manage the implications of the new voting structure.
• Ehave Inc. may choose to convert its preferred stock into common stock in the future.
• The company will need to ensure compliance with all relevant regulations and reporting requirements.

Key Dates

Keywords

Super Voting Stock, Preferred Stock, Shareholder Agreement, Voting Rights, Capital Structure, Corporate Governance, Ehave Inc., Mycotopia Therapies, Stock Conversion, Common Stock